AKKARAJU SRINIVAS
SEC CIK 1253170 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ALMS | ALUMIS INC. | Dir | 2.30M | $56.27M | $1.01M | 16 | 2024-07-01 | 2026-09-08 |
| SRRK | Scholar Rock Holding Corp | Dir, 10% | 28.0K | $34.99M | $34.39M | 8 | 2023-10-16 | 2026-06-04 |
| KLRS | Kalaris Therapeutics, Inc. | Dir, 10% | 2.22M | $1.18M | — | 4 | 2025-03-18 | 2026-05-20 |
| MLYS | Mineralys Therapeutics, Inc. | Dir, 10% | 6,200 | $38.10M | — | 6 | 2023-02-14 | 2026-02-19 |
| VTVT | vTv Therapeutics Inc. | Dir, 10% | 106.0K | — | — | 3 | 2024-02-27 | 2025-09-22 |
| NGNE | Neurogene Inc. | 10% | 1.69M | $1.26M | — | 1 | 2024-11-26 | 2024-11-26 |
| LENZ | LENZ Therapeutics, Inc. | 10% | 8.11M | $16.23M | — | 7 | 2021-06-29 | 2022-04-11 |
Most active insiders at ALMS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | AKKARAJU SRINIVAS | Dir | $29.80M | $1.01M |
| 2 | Tananbaum James B. | Dir, 10% | $10.63M | — |
| 3 | Foresite Labs Fund I, L.P. | 10% | $7.53M | — |
| 4 | Foresite Labs, LLC | 10% | $7.00M | — |
| 5 | Foresite Labs Affiliates 2021, LLC | 10% | $3.63M | — |
| 6 | Foresite Capital Management VI LLC | 10% | $3.09M | — |
| 7 | Pangali Sanam | CLO | — | $176.0K |
| 8 | Schroer John R. | CFO | — | $86.5K |
| 9 | Hardiman Roy C. | Chief Business, Strategy Ofcr | — | $71.0K |
| 10 | Goldstein David M | CSO | — | $68.5K |
Transactions 45
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2026-09-09 21:39 | 2026-09-04+ | ALMS | ALUMIS INC. | AKKARAJU SRINIVAS | Dir | P - Purchase | $10.87 | +986.7K | 2.30M | +75% | +$10.73M |
| MI | 2026-09-09 21:39 | 2026-09-08 | ALMS | ALUMIS INC. | AKKARAJU SRINIVAS | Dir | S - Sale | $10.55 | -96.1K | 2.03M | -5% | -$1.01M |
| D | 2026-07-02 18:22 | 2026-06-30 | ALMS | ALUMIS INC. | AKKARAJU SRINIVAS | Dir | A - Grant | $0.00 | +3,553 | 3,553 | New | $0 |
| D | 2026-06-08 16:48 | 2026-06-04 | SRRK | Scholar Rock Holding Corp | AKKARAJU SRINIVAS | Dir | A - Grant | $0.00 | +6,839 | 28.0K | +32% | $0 |
| I | 2026-05-22 19:47 | 2026-05-20 | KLRS | Kalaris Therapeutics, Inc. | AKKARAJU SRINIVAS | Dir, 10% | P - Purchase | $4.83 | +244.3K | 2.22M | +12% | +$1.18M |
| MI | 2026-05-22 19:47 | 2026-05-20 | KLRS | Kalaris Therapeutics, Inc. | AKKARAJU SRINIVAS | Dir, 10% | J - Other | $0.00 | -47.5K | 19.4K | -71% | $0 |
| D | 2026-02-20 | 2026-02-19 | MLYS | Mineralys Therapeutics, Inc. | AKKARAJU SRINIVAS | Dir, 10% | A - Grant | $0.00 | +6,200 | 6,200 | New | $0 |
| I | 2026-01-13 | 2026-01-09 | ALMS | ALUMIS INC. | AKKARAJU SRINIVAS | Dir | P - Purchase | $17.00 | +588.2K | 1.85M | +46% | +$10.00M |
| I | 2025-12-22 | 2025-12-22 | KLRS | Kalaris Therapeutics, Inc. | AKKARAJU SRINIVAS | Dir, 10% | A - Grant | $10.00 | +1.50M | 1.50M | New | +$15.00M |
| DI | 2025-12-16 | 2025-12-12 | SRRK | Scholar Rock Holding Corp | AKKARAJU SRINIVAS | Dir | X - OptEx | $7.35 | +1.06M | 6.37M | +20% | +$7.83M |
| DMI | 2025-12-16 | 2025-10-07 | SRRK | Scholar Rock Holding Corp | AKKARAJU SRINIVAS | Dir | P - Purchase | $39.92 | +29.6K | 525.6K | +6% | +$1.18M |
| MI | 2025-12-09 | 2025-12-05 | ALMS | ALUMIS INC. | AKKARAJU SRINIVAS | Dir | P - Purchase | $9.84 | +186.4K | 1.14M | +19% | +$1.83M |
| MI | 2025-12-04 | 2025-12-02+ | ALMS | ALUMIS INC. | AKKARAJU SRINIVAS | Dir | P - Purchase | $7.79 | +262.0K | 912.8K | +40% | +$2.04M |
| MI | 2025-12-01 | 2025-11-26+ | ALMS | ALUMIS INC. | AKKARAJU SRINIVAS | Dir | P - Purchase | $7.55 | +173.6K | 691.8K | +33% | +$1.31M |
| I | 2025-11-24 | 2025-11-20 | ALMS | ALUMIS INC. | AKKARAJU SRINIVAS | Dir | P - Purchase | $7.20 | +125.7K | 643.3K | +24% | +$905.3K |
| MI | 2025-11-19 | 2025-11-17+ | ALMS | ALUMIS INC. | AKKARAJU SRINIVAS | Dir | P - Purchase | $6.34 | +241.3K | 379.7K | +174% | +$1.53M |
| I | 2025-11-17 | 2025-11-13 | ALMS | ALUMIS INC. | AKKARAJU SRINIVAS | Dir | P - Purchase | $5.25 | +276.2K | 276.2K | New | +$1.45M |
| MI | 2025-10-07 | 2025-10-03+ | SRRK | Scholar Rock Holding Corp | AKKARAJU SRINIVAS | Dir | P - Purchase | $37.58 | +500.4K | 486.7K | New | +$18.81M |
| DI | 2025-09-25 | 2025-09-22 | VTVT | vTv Therapeutics Inc. | AKKARAJU SRINIVAS | Dir | A - Grant | $15.27 | +106.0K | 106.0K | New | +$1.62M |
| I | 2025-09-08 | 2025-09-04 | MLYS | Mineralys Therapeutics, Inc. | AKKARAJU SRINIVAS | Dir | P - Purchase | $25.50 | +588.2K | 588.2K | New | +$15.00M |
| I | 2025-05-23 | 2025-05-21 | ALMS | ALUMIS INC. | AKKARAJU SRINIVAS | Dir | A - Grant | — | +1.21M | 4.80M | +34% | — |
| D | 2025-05-23 | 2025-05-22 | SRRK | Scholar Rock Holding Corp | AKKARAJU SRINIVAS | Dir | A - Grant | $0.00 | +7,632 | 21.1K | +57% | $0 |
| MI | 2025-05-06 | 2025-05-02+ | ALMS | ALUMIS INC. | AKKARAJU SRINIVAS | Dir | P - Purchase | $4.61 | +320.3K | 3.56M | +10% | +$1.48M |
| I | 2025-03-18 | 2025-03-18 | KLRS | Kalaris Therapeutics, Inc. | AKKARAJU SRINIVAS | Dir, 10% | A - Grant | — | +11.44M | 11.44M | New | — |
| I | 2025-03-17 | 2025-03-13 | MLYS | Mineralys Therapeutics, Inc. | AKKARAJU SRINIVAS | Dir | P - Purchase | $13.50 | +600.0K | 5.67M | +12% | +$8.10M |
| DI | 2024-12-06 | 2024-03-05 | VTVT | vTv Therapeutics Inc. | AKKARAJU SRINIVAS | Dir, 10% | D - Sale to Iss | — | -58.8K | 206.8K | -22% | — |
| MI | 2024-11-27 | 2024-11-26 | NGNE | Neurogene Inc. | AKKARAJU SRINIVAS | 10% | P - Purchase | $25.83 | +48.8K | 1.69M | +3% | +$1.26M |
| MI | 2024-10-07 | 2024-10-07 | SRRK | Scholar Rock Holding Corp | AKKARAJU SRINIVAS | Dir | S - Sale | $29.25 | -1.18M | 5.77M | -17% | -$34.39M |
| AI | 2024-08-27 | 2024-07-01 | ALMS | ALUMIS INC. | AKKARAJU SRINIVAS | Dir | P - Purchase | $16.00 | +1.56M | 3.27M | +92% | +$25.00M |
| D | 2024-07-01 | 2024-06-27 | SRRK | Scholar Rock Holding Corp | AKKARAJU SRINIVAS | Dir | A - Grant | $0.00 | +13.5K | 13.5K | New | $0 |
| DI | 2024-07-01 | 2024-07-01 | ALMS | ALUMIS INC. | AKKARAJU SRINIVAS | Dir | C - Cnv Deriv | — | +1.70M | 1.70M | New | — |
| DI | 2024-07-01 | 2024-07-01 | ALMS | ALUMIS INC. | AKKARAJU SRINIVAS | Dir | A - Grant | — | +1.70M | 1.70M | New | — |
| DI | 2024-07-01 | 2024-07-01 | ALMS | ALUMIS INC. | AKKARAJU SRINIVAS | Dir | D - Sale to Iss | — | -1.70M | 0 | -100% | — |
| DI | 2024-02-29 | 2024-02-27 | VTVT | vTv Therapeutics Inc. | AKKARAJU SRINIVAS | Dir, 10% | A - Grant | $11.81 | +224.7K | 265.6K | +550% | +$2.65M |
| I | 2024-02-14 | 2024-02-12 | MLYS | Mineralys Therapeutics, Inc. | AKKARAJU SRINIVAS | Dir, 10% | A - Grant | $13.50 | +555.6K | 5.07M | +12% | +$7.50M |
| I | 2023-10-18 | 2023-10-16 | SRRK | Scholar Rock Holding Corp | AKKARAJU SRINIVAS | Dir, 10% | P - Purchase | $6.85 | +2.19M | 6.79M | +48% | +$15.00M |
| DI | 2023-02-16 | 2023-02-14 | MLYS | Mineralys Therapeutics, Inc. | AKKARAJU SRINIVAS | Dir, 10% | C - Cnv Deriv | — | +3.58M | 3.58M | New | — |
| DI | 2023-02-16 | 2023-02-14 | MLYS | Mineralys Therapeutics, Inc. | AKKARAJU SRINIVAS | Dir, 10% | P - Purchase | $16.00 | +937.5K | 4.52M | +26% | +$15.00M |
| MI | 2022-04-13 | 2022-04-11+ | LENZ | LENZ Therapeutics, Inc. | AKKARAJU SRINIVAS | 10% | P - Purchase | $4.08 | +424.5K | 8.11M | +6% | +$1.73M |
| MI | 2022-01-25 | 2022-01-21+ | LENZ | LENZ Therapeutics, Inc. | AKKARAJU SRINIVAS | 10% | P - Purchase | $8.94 | +123.0K | 8.01M | +2% | +$1.10M |
| MI | 2022-01-21 | 2022-01-19+ | LENZ | LENZ Therapeutics, Inc. | AKKARAJU SRINIVAS | 10% | P - Purchase | $9.10 | +97.7K | 7.91M | +1% | +$888.7K |
| I | 2021-11-24 | 2021-11-22 | LENZ | LENZ Therapeutics, Inc. | AKKARAJU SRINIVAS | 10% | P - Purchase | $10.15 | +201.7K | 7.79M | +3% | +$2.05M |
| MI | 2021-10-08 | 2021-10-06+ | LENZ | LENZ Therapeutics, Inc. | AKKARAJU SRINIVAS | 10% | P - Purchase | $13.53 | +145.5K | 7.46M | +2% | +$1.97M |
| DMI | 2021-07-01 | 2021-06-29 | LENZ | LENZ Therapeutics, Inc. | AKKARAJU SRINIVAS | 10% | P - Purchase | $17.00 | +500.0K | 7.39M | +7% | +$8.50M |
| DMI | 2021-07-01 | 2021-06-29 | LENZ | LENZ Therapeutics, Inc. | AKKARAJU SRINIVAS | 10% | C - Cnv Deriv | — | +6.93M | 6.91M | New | — |
Purchase Sale Sale after option exercise All abbreviations